AU2016336133B2 - Combination therapies for treating cancer - Google Patents

Combination therapies for treating cancer Download PDF

Info

Publication number
AU2016336133B2
AU2016336133B2 AU2016336133A AU2016336133A AU2016336133B2 AU 2016336133 B2 AU2016336133 B2 AU 2016336133B2 AU 2016336133 A AU2016336133 A AU 2016336133A AU 2016336133 A AU2016336133 A AU 2016336133A AU 2016336133 B2 AU2016336133 B2 AU 2016336133B2
Authority
AU
Australia
Prior art keywords
cancer
phenyl
agents
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016336133A
Other languages
English (en)
Other versions
AU2016336133A1 (en
Inventor
Danielle Abramson
Dror BEN-ASHER
Reza Fathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of AU2016336133A1 publication Critical patent/AU2016336133A1/en
Application granted granted Critical
Publication of AU2016336133B2 publication Critical patent/AU2016336133B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016336133A 2015-10-06 2016-10-06 Combination therapies for treating cancer Ceased AU2016336133B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237925P 2015-10-06 2015-10-06
US62/237,925 2015-10-06
PCT/IB2016/001526 WO2017060771A2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Publications (2)

Publication Number Publication Date
AU2016336133A1 AU2016336133A1 (en) 2018-03-15
AU2016336133B2 true AU2016336133B2 (en) 2021-02-25

Family

ID=58446480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016336133A Ceased AU2016336133B2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Country Status (12)

Country Link
US (4) US9844540B2 (enExample)
EP (1) EP3359255A4 (enExample)
JP (1) JP6963545B2 (enExample)
KR (1) KR20180058716A (enExample)
CN (1) CN108136207A (enExample)
AU (1) AU2016336133B2 (enExample)
BR (1) BR112018003232A2 (enExample)
CA (1) CA2997671A1 (enExample)
HK (1) HK1259342A1 (enExample)
MX (1) MX382754B (enExample)
RU (1) RU2727474C2 (enExample)
WO (1) WO2017060771A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134076A1 (en) 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3644988B1 (en) 2017-06-26 2023-02-22 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
EP3681494A4 (en) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES
BR112021013952A2 (pt) * 2019-01-16 2021-11-16 Apogee Biotechnology Corp Métodos de indução de uma resposta imunológica anticâncer
WO2020154716A1 (en) * 2019-01-26 2020-07-30 University Of Rochester Compositions and methods for treating prostate cancer
CA3174438A1 (en) * 2020-03-10 2021-09-16 Redhill Biopharma Ltd. Treatment of coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007957A1 (en) * 2001-07-17 2003-01-30 Unisearch Limited Method and composition for treatment of cancer
US20060142304A1 (en) * 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
US20120095004A1 (en) * 2005-06-17 2012-04-19 Apogee Biotechnology Corporation Sphingosine Kinase Inhibitors
US9134329B2 (en) * 2012-08-30 2015-09-15 The Texas A&M University System Compositions and methods for drug-sensitization or inhibition of a cancer cell

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
DE59909210D1 (de) * 1998-07-20 2004-05-19 Wilex Ag Urokinase-Inhibitoren
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
HRP20190045T1 (hr) * 2008-02-08 2019-03-08 Red Hill Biopharma Ltd. Metode i sastavi za liječenje upalne bolesti crijeva
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
EP4134076A1 (en) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007957A1 (en) * 2001-07-17 2003-01-30 Unisearch Limited Method and composition for treatment of cancer
US20060142304A1 (en) * 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
US20120095004A1 (en) * 2005-06-17 2012-04-19 Apogee Biotechnology Corporation Sphingosine Kinase Inhibitors
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
US9134329B2 (en) * 2012-08-30 2015-09-15 The Texas A&M University System Compositions and methods for drug-sensitization or inhibition of a cancer cell

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BELJANSKI et al., "Combined anticancer effects of sphingosine kinase inhibitors and sorafenib", Invest New Drugs., (2011), vol. 29, no. 6, pages 1132 - 1142 *
FRORIEP DANILO ET AL, "Activation of the anti-cancer agent upamostat by the mARC enzyme system", XENOBIOTICA,, vol. 43, no. 9, doi:10.3109/00498254.2013.767481, ISSN 1366-5928, (2013-08-31), pages 780 - 784, (2013-02-04) *

Also Published As

Publication number Publication date
US20170095460A1 (en) 2017-04-06
CN108136207A (zh) 2018-06-08
MX382754B (es) 2025-03-13
US11633385B2 (en) 2023-04-25
WO2017060771A3 (en) 2017-07-06
RU2018109902A3 (enExample) 2020-03-05
JP6963545B2 (ja) 2021-11-10
KR20180058716A (ko) 2018-06-01
US20210128538A1 (en) 2021-05-06
HK1259342A1 (zh) 2019-11-29
MX2018004309A (es) 2018-05-22
US10463654B2 (en) 2019-11-05
EP3359255A2 (en) 2018-08-15
AU2016336133A1 (en) 2018-03-15
BR112018003232A2 (pt) 2018-09-25
US10946000B2 (en) 2021-03-16
CA2997671A1 (en) 2017-04-13
WO2017060771A2 (en) 2017-04-13
JP2018533560A (ja) 2018-11-15
US20200113881A1 (en) 2020-04-16
RU2727474C2 (ru) 2020-07-21
RU2018109902A (ru) 2019-11-07
EP3359255A4 (en) 2019-06-12
US9844540B2 (en) 2017-12-19
US20180125831A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
AU2016336133B2 (en) Combination therapies for treating cancer
US20140051662A1 (en) Treatment of multiple myeloma with masitinib
EP2303274A1 (en) Multiple myeloma treatments
EP3967310B1 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
EP3878444B1 (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
CN115969975B (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
CN108299390B (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
BR112020009596A2 (pt) combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
RU2252761C2 (ru) Лечение случайной транссудации антрациклинов
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
US20210128683A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
EP3854411A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
CN117835974A (zh) 使用bcl-2抑制剂治疗b细胞恶性肿瘤的方法
HK1246085B (en) Anticancer therapeutic agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired